Found in Translation: Reasons for Optimism in the Pursuit to Prevent Chronic Kidney Disease After Acute Kidney Injury

Samuel A. Silver¹ and Casimiro Gerarduzzi²,³

Abstract
Purpose of review: The current review will discuss on the progress of studying the transition phase between acute kidney injury (AKI) and chronic kidney disease (CKD) through improved animal models, common AKI and CKD pathways, and how human studies may inform different translational approaches.

Sources of information: PubMed and Google Scholar.

Methods: A narrative review was performed using the main terms “acute kidney injury,” “chronic kidney disease,” “end-stage renal disease,” “animal models,” “review,” “decision-making,” and “translational research.”

Key findings: The last decade has shown much progress in the study of AKI, including evidence of a pathophysiological link between AKI and CKD. We are now in a phase of redesigning animal models and discovering mechanisms that can replicate the pathological conditions of the AKI-to-CKD continuum. Translating these findings into the clinic is a barrier that must be overcome. To this end, current efforts include prediction of AKI onset and maladaptive repair, detecting patients susceptible to the progression of chronic maladaptive repair, and understanding shared signaling mechanisms between AKI and CKD.

Limitations: This is a narrative review of the literature that is partially influenced by the knowledge, perspectives, and experiences of the authors and their research background.

Implications: Overall, this new knowledge from the AKI-to-CKD continuum will help bridge the discontinuity that exists between animal models and patients, resulting in more effective translational biomarkers and therapeutics to test in known AKI pathologies thereby preventing the chronicity of kidney injury progression.

Abridged
Justification: La présente revue porte sur l’avancement des connaissances relatives à la phase de transition entre l’insuffisance rénale aiguë (IRA) et l’insuffisance rénale chronique (IRC) grâce à des modèles animaux améliorés, à l’étude des mécanismes communs à l’IRA et l’IRC, et à la contribution que la recherche chez l’humain peut apporter aux différentes approches translationnelles.

Sources: PubMed et Google Scholar.

Méthodologie: Une revue narrative a été réalisée à l’aide des principaux termes suivants: insuffisance rénale aiguë (acute kidney disease), insuffisance rénale chronique (chronic kidney disease), insuffisance rénale terminale (end-stage renal disease), modèles animaux (animal models), revue (review), prise de décision (decision making) et recherche translationnelle (translational research).

Principaux Résultats: La dernière décennie a été marquée par de nombreux progrès dans l’étude de l’IRA, notamment par la mise en évidence d’un lien physiopathologique entre l’IRA et l’IRC. Nous en sommes actuellement à développer de nouveaux modèles animaux et à élaborer des mécanismes pouvant reproduire les conditions pathologiques du continuum IRA-IRC. Transposer ces résultats en clinique est un obstacle à surmonter. C’est pourquoi, les efforts déployés actuellement incluent la prédiction du début de l’IRA et d’une récupération rénale inadéquate, la détection des patients susceptibles de progresser vers une récupération rénale inadéquate à long terme et la compréhension des mécanismes de signalisation communs à l’IRA et l’IRC.

Limites: Il s’agit d’une revue narrative de la littérature qui est en partie influencée par les connaissances, les perceptions et les expériences des auteurs, de même que par leur formation antérieure en recherche.

Conclusion: Dans l’ensemble, ces nouvelles connaissances tirées du continuum menant de l’IRA à l’IRC aideront à combler les lacunes entre les modèles animaux et les patients, ce qui permettra de mettre au point des biomarqueurs translationnels.
et des traitements plus efficaces à tester sur les pathologies menant à l'IRA, dans le but de prévenir la progression et la chronicité de la maladie.

Keywords
acute kidney injury, animal models, chronic kidney disease, end-stage renal disease, translational research

Received April 30, 2019. Accepted for publication June 21, 2019.

What was known before? (why is this review important)
Acute kidney injury (AKI) is a common complication of acute illness and a growing public health concern. Much progress has been made in understanding the pathogenesis, progression, and repair of AKI, but unfortunately few therapeutic agents have improved patient outcomes.

What this adds
Review of potential strategies to translate knowledge of AKI into the prevention of chronic kidney disease and end-stage renal disease at the bedside, with an emphasis on both traditional translational research (bench to bedside) and reverse translational research (starting with human studies to inform mechanisms that are validated in the laboratory setting).

What are the key messages?
More knowledge of human AKI at the tissue level is needed along with validation of these discoveries in multiple animal models that mirror the complexities of human AKI. Promising therapeutic agents should then be tested in high-risk patients with known causes of AKI in whom the timing of AKI onset or transition to maladaptive repair can also be determined. Teamwork and stakeholder engagement will be critical to these efforts, which must involve patients given the increasing emphasis on human tissue.

Introduction
Acute kidney injury (AKI) is a common complication of acute illness that affects as many as 20% of hospitalized patients.1,2 While the in-hospital morbidity and mortality associated with AKI is well-described,3 it is now clear that individuals who survive to leave the hospital after an episode of AKI are at persistent risk of adverse kidney outcomes.5,6 For example, a meta-analysis demonstrated that compared to patients without AKI, survivors of AKI have an almost 10-fold greater risk of developing de novo chronic kidney disease (CKD) and a 3-fold greater risk of end-stage renal disease (ESRD).6 Based upon an AKI population incidence of 2147 per million people, it is estimated that in the developed world (United States, Canada, Europe, and Australia/New Zealand), there will be more than 2 million cases of AKI annually, of which 3% to 15% will develop ESRD and 20% to 50% will progress to CKD.7 The majority of these cases will be due to decreased kidney perfusion (i.e., pre-renal, sepsis, cardiac failure) and nephrotoxic medications, with small overall contributions from glomerulonephritis, interstitial nephritis, and obstruction.5,9 The incidence of AKI has increased over the last 15 years and is expected to double over the next decade,7 suggesting that AKI and its association with progressive CKD and ESRD represents a growing public health burden.

Clearly, the lack of effective therapeutic interventions for the prevention or treatment of AKI is a major unmet medical need. Several workshops have recently assembled to identify and overcome barriers in the translation of basic knowledge of AKI into the prevention of CKD and ESRD.10-13 Much progress has been made in understanding the pathogenesis, progression, and repair of AKI, which has resulted in numerous potential therapeutic agents to evaluate. However, AKI has many different etiologies, and the timing of its onset in humans is often unpredictable; these latter factors have minimized the human health impact of basic knowledge gained from preclinical and animal models of AKI. Notwithstanding

1Division of Nephrology, Kingston Health Sciences Center, Queen’s University, Kingston, ON, Canada
2Division de Néphrologie, Centre de recherche de l’Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada
3Département de Médecine, Faculté de Médecine, Université de Montréal, Montréal, Québec, Canada

Corresponding Authors:
Samuel A. Silver, Division of Nephrology, Kingston Health Sciences Center, Queen’s University, 76 Stuart Street, 3-Burr 21-3-039, Kingston, ON K7L 2V7, Canada.
Email: samuel.silver@queensu.ca

Casimiro Gerarduzzi, Division de Néphrologie, Centre de recherche de l’Hôpital Maisonneuve-Rosemont, 5345, boulevard de l’Assomption, Montreal, QC H1T 2M4, Canada.
Email: casimiro.gerarduzzi@umontreal.ca
these challenges, substantial optimism exists that past “failures” will soon produce effective interventions to prevent and treat AKI thereby lessening its long-term sequelae. Although there are several approaches to describe the progression of AKI research, this review will be limited to detail some key reasons for this positive outlook, focusing on the current state and barriers affecting AKI research, recent examples of successful therapeutic interventions, and how these lessons may inform future AKI translational research.

Current State of Basic Science Research

One of the major difficulties we face in understanding the kidney is narrowing the knowledge gap that exists between animal model discoveries and clinical observations. Partly, AKI is difficult to reproduce within animal models given its complexity and multifaceted etiology. Over the years, animal models have improved from defining a specific injury with a unique maladaptive repair response of fibrosis to recent animal studies proposing that the repetitive exposure and variation in dosages are fundamental in influencing the outcomes of AKI and its continuum into CKD, regardless of the initial insult.11,14 These AKI-to-CKD transition models are capable of recapitulating the pathological mechanism of maladaptive repair that commences in the tubular region during an AKI response, reduces kidney structure and function, and propagates into interstitial fibrosis throughout CKD. This is translatable to human studies because the severity of injury can influence a variety of integral repair mechanisms to be continually activated in a maladaptive fashion from AKI to a CKD response. For example, continual expansion of activated fibroblasts, which are the effector cells of fibrosis, is found within AKI and CKD due to a persistent injury signal irrespective of the type of injury.15 This is also the case with reduced capillary density, which is found in both AKI and CKD and leads to hypoxia-induced fibrosis.16 Full comprehension of these common pathological mechanisms between AKI and CKD can fashion an approach to better target the progression of CKD in the post-AKI setting.

Conventional animal models used to study the AKI-to-CKD transition have been designed through modification of the ischemia/reperfusion injury (IRI) and nephrotoxicity models. In addition to the dosage of injury, these redesigned animal models are also established on the timing of injury so as to develop effective therapies that are based on a rationale for targeted treatments at specific time points between the AKI-CKD continuum. Consequently, such models will help determine dosage-responsive targets and crucial time points needed to develop effective therapies of intervention. Overall, the following described IRI and nephrotoxicity models are designed to permit the kidney to recover from an initial insult by triggering de-differentiation and proliferation of the remaining damaged cells following an episode of AKI, but enter CKD with a more severe injury based on longer timing and higher/repeated dosage of injury.

IRI Models

One of the main causes of AKI is IRI due to various clinical procedures of clamping of vessels during renal transplantation and postoperative decrease in perfusion. Multiple species have been used to recapitulate IRI for specific requirements. Larger species (pigs and dogs) are used for their resemblance in anatomy and size to humans for surgical-like procedures that induce IRI. Rodents are commonly used to study IRI because of the availability of genetically modified models and their ability to generate large sample sizes due to short breeding periods. IRI is a simple and reproducible procedure induced by temporarily clamping the arteriole blood flow and restoring it for redistribution of oxygen and nutrient delivery.17,18 Within mouse models, the kidney hilum is clamped between 30 and 60 minutes followed by reperfusion for days to weeks to cause a post-ischemic response reflective of an AKI to CKD transition.17-19 This impairment subsequently leads to the acute pathological changes of early inflammation, tubular dilatation and necrosis, significantly elevated creatinine levels and brush border loss within days to chronic events of sustained inflammation, interstitial fibrosis, and tubular atrophy.17,20 Body temperature fluctuation is one of the most important factors affecting the severity of experimental IRI, that is, lower temperatures cause less damage; therefore, a homeothermic monitor system and heating pad must be used to accurately keep mice warm during surgery.18,21,22

Nephrotoxic Models

By virtue of its primary role in clearing toxicants from the blood, the kidney is inherently vulnerable to nephrotoxic injury due to its continuous exposure to such harmful contaminants. Several nephrotoxic models have been developed to generate injuries throughout the AKI-to-CKD transition toward CKD progression using various repeated treatments and/or dosages of toxins, such as folic acid (FA), cisplatin, and aristolochic acid (AA). FA is a simple injury model commonly performed on rodents using a dosage and timing with toxicokinetics comparable to those associated with disease in humans.23,24 FA is a nephrotoxicant which crystallizes in the epithelial tubules at high doses. Consequently, this results in tubular lesions, intratubular crystal-obstruction, and a direct toxic effect on the epithelial cells,25 accompanied by mild fibrosis in the chronic phase. Remarkably, these same injury characteristics are found in patients with AKI, suggesting the FA-injury model to be relevant to human AKI mechanisms.26 Cisplatin is a widely used chemotherapy drug with a nephrotoxic effect that is cumulative and dose-dependent.27 The notable pathophysiological effects of cisplatin include proximal tubular and vascular injury and necrosis leading to chronic inflammation and fibrosis reflective of CKD development.28-32 AA is a chemical agent commonly found in the Aristolochiaceae plant family that has nephrotoxic effects. Notably, the AA model offers a more directly translatable opportunity to study nephrotoxological mechanisms in
Cellular Senescence and Associated Pathways

One of the earliest response pathways that is activated in injured tubular epithelial cells (TECs) from an AKI model is p53-mediated G2/M cell cycle arrest, which consequently leads to the program of senescence. Cellular senescence is involved in normal wound healing by producing a distinct secretome, termed the senescence-associated secretory phenotype (SASP), of pro-repair and pro-inflammatory factors. In particular, G2/M-arrested tubular cells were noted for their increase in c-jun NH2-terminal kinase (JNK) signaling, which is known to enhance the gene transcription of the major profibrotic factor, TGF-β. Although the expression of TGFβ is needed to stimulate proliferation of tubular cells for regeneration during early injury states of AKI, the prolonged state of cell cycle arrest in CKD results in a TGFβ signaling pathway that is continuously activated to induce the chronic renal fibrotic events of fibroblast activation and extracellular matrix production. Furthermore, prolonged TGFβ can also contribute to the senescent phenotype of renal proximal TECs by stimulating IGF-binding protein 7 (IGFBP7), which is a component of the SASP.

Inflammation Pathways

Pro-inflammatory factors are important constituents of the SASP during the communication of the senescent tubule to its neighboring cells, in particular by producing interleukin 6 (IL-6) and TNF-α. Within the AKI model, the IL-6 signaling axis was implicated in activating an injurious inflammatory response, whose chronic activation led to CKD fibrotic features. In the cisplatin AKI model, TNF-α was shown to play a central role in the activation of pro-inflammatory cytokine response, while two separate studies confirmed the association of circulating TNF-α and its receptors with progression of CKD.

Epigenetic Pathways

Diverse epigenetic mechanisms are known to promote pro-inflammatory and profibrotic gene expression. The most common epigenetic modifications seen with acute and chronic kidney diseases include DNA methylation and histone acetylation/deacetylation. An IRI AKI-to-CKD transition mouse model provided evidence of the overlapping mechanism of progressive histone modifications at specific pro-inflammatory/profibrotic genes, such as MCP-1, TGFβ, and collagen. A common epigenetic modification during AKI involves a TGFβ-driven hypermethylation and silencing of the RASAL1 gene, an inhibitor of RAS. Consequently, RAS is continuously activated to drive fibroblast activation and proliferation, which overtime induces an CKD transition. Furthermore, inhibitors of histone deacetylation were shown to attenuate kidney injury and the development of AKI-to-CKD in models of AA-, cisplatin-, and ischaemic-induced kidney injuries, potentially describing the importance of regulating epigenetic outcomes during the transition of AKI to CKD.

Developmental Pathways

Injured tissues enter a regenerative phase that recapitulates key developmental pathways. Wnt and Notch signaling are canonical pathways that regulate morphogenesis and progenitor populations during development. Expression of Wnt and Notch diminishes once nephrogenesis is complete; however, during an injury, the kidney epithelium reactivates the Wnt and Notch pathways to re-establish the tubular microanatomy. Both Wnt and Notch are upregulated during AKI;
however, their sustained activation drives AKI-to-CKD progression by promoting fibroblast activation and fibrotic matrix deposition. Specifically, Wnt4 ligand signaling through β-catenin stabilization is sufficient to drive the myo-fibroblast marker αSMA in kidney interstitial stromal cells in the absence of an injury signal, resulting in these effector cells to drive fibrosis in uninjured kidneys. In the case with Notch signaling, the Notch-2 receptor and its ligand Delta-1 have been implicated in the proliferation of renal tubules during AKI, while Notch-1 and Delta-4 play key roles in fibrosis development.

In summary, advancing our animal models to reflect the clinical progression of AKI to CKD is needed to delve into the mechanisms of action and pave the way for improved clinical translation. As we continue to develop and refine our AKI-to-CKD models and identify their continuum pathways, we will be in a better position to clarify their causal relationship for preclinical testing of potential diagnostic and therapeutic approaches.

Transition From Animal Models to Patients

Animal models provide the means to accelerate the discovery and evaluation of targets and pathways, which are then assessed in patients on whether they are modulated and serve as primary drivers of pathogenesis. As discussed above, animal models of the AKI-to-CKD transition have provided a better understanding that the pathways of senescence, inflammation, epigenetics, and development are implicated in the continuum between both states of kidney disease. As such, targeting the mechanisms of these pathways has potential for intercepting the transition from AKI to CKD. Several promising targets have been discovered from such AKI-to-CKD models. For example, p53 inhibitors have shown promise of inhibiting senescence and SASP in preventing the progression from AKI to CKD. Apart from acting as potential therapeutic targets, molecules from these pathways could also serve as biomarkers since current methods are imperfect and poorly reflect the measurement of kidney function. For example, some traditional methods that evaluate the degree of nephropathology, which include measuring GFR by creatinine levels and fibrosis by collagen deposition, detect kidney injury at stages when there has been sufficient damage. However, translation of AKI-to-CKD relevant biochemical pathways offers potential for effective therapies. Specifically, detection of subtle changes in genetic modifications and molecular pathways implicated in the AKI-to-CKD continuum during the early stages of AKI before their transition into CKD could offer better preventative measures against the irreversible states of kidney damage. For example, studies involving patients with AKI have been reported to have genes with DNA methylations and histone modifications that altered their transcription and subsequently implicated in renal injury. Therefore, future studies are needed to delineate the timing of AKI-to-CKD transition pathways to optimize any of their protective effects but prevent the outcomes of their chronic activation. Moreover, genomic and proteomic techniques would offer an opportunity to discover, validate, and gather the dynamic expression of numerous targets and better grasp their role in the pathogenesis of kidney injury.

Overcoming Limitations

Progress has been made in developing mouse models that closely relate to the progression of CKD from AKI in patients. There is a need to find better strategies to identify therapeutic targets from studies coming from animal models that can relate to human nephropathologies. This is a major concern because of the high cost of conducting clinical trials. One way to increase the chances of a translatable target into humans could potentially come from targets that have conserved effects and/or pharmacokinetic properties across various species. Furthermore, the study of multiple AKI-to-CKD transition models may help identify conserved pathways in the AKI-to-CKD continuum. Animal models also tend to have limitations in reproducing, or at the very least resembling, human disease due to differences in physiology/pathophysiology between animals and humans, and also to faulty experimental procedures or models that simplify insults for complex clinical states. A solution would be to use emerging concepts from patient data as a guide to recapitulate expected results by fine-tuning animal models. As a result, the in vivo modeling of patient data would permit a lower occurrence of false positives and higher certainty of therapeutic targets emanating from detailed mechanisms. Overall, studies should be rigorously designed and executed, taking into consideration strain background, diet, and other relevant variables, and be conducted in a blinded manner.

Current State of AKI Clinical Research

To take full advantage of the animal models and mechanisms described above, subsequent studies in humans should closely resemble the conditions in which the therapeutic interventions were initially discovered. This creates challenges because the onset of AKI and transition to CKD in humans can be difficult to recognize, and the mechanism used to induce injury in animal models may not replicate the multiple etiologies responsible for AKI and CKD progression in humans. To this end, much progress has been made in the ability to identify and predict patients at high risk for AKI and CKD progression. Koyner et al. integrated a multicenter risk algorithm into the electronic health record of 202,961 hospitalized patients over a 4-year period. Using routinely collected data readily available in the electronic chart, patients at risk for Kidney Disease Improving Global Outcomes (KDIGO) stages 1 and 3 AKI
were identified in real-time, a median 42 and 35 hours before AKI onset. For patients at risk for CKD progression, James et al.\(^7\) developed a six-variable prediction equation in 9973 patients. Readily available online and remotely (qxmd.com), this simple tool accurately identifies progression to stage 4 CKD within 1 year of hospital discharge. Both studies highlight that there is sufficient time to deliver therapeutic interventions to patients at high risk for AKI and CKD before these events occur.

Progress has similarly been achieved in the rapid identification of patients with established AKI, though less so with CKD progression after AKI. Currently, the detection of AKI relies primarily on serum creatinine concentration and urine output\(^7\); however, there are few symptoms that accompany AKI and CKD which often leads to delays in the recognition and treatment of these conditions. The introduction of electronic creatinine alert systems for AKI, which notify healthcare providers within minutes of creatinine elevation, helps address this problem. These alert systems have been scaled nationally in the United Kingdom, demonstrating their feasibility. In a multicenter study of 24,059 AKI episodes, an electronic creatinine alert coupled with a care bundle increased the detection of AKI, medication reviews, and fluid assessments.\(^7\) While this UK study and another study in the United States of 2400 patients failed to reduce AKI severity and mortality,\(^7,6\) they demonstrate the capacity to rapidly identify established AKI in real-time. The disappointing results may relate to the insensitive nature of serum creatinine; it is non-specific and only elevates after injury has already occurred, which is a principle that also applies to the identification of maladaptive repair after AKI.

Accordingly, biomarkers have been sought to aid in detection of subclinical injury, provide information on the etiology and anatomic location of AKI, detail the extent of damage, and measure ongoing injury and/or repair/fibrosis after AKI.\(^7\) Biomarkers of tubular injury such as IL-18,\(^7,8\) neutrophil gelatinase-associated lipocalin (NGAL),\(^7,9\) and KIM-1\(^10\) can differentiate between pre-renal azotemia and acute tubular injury, but their modest discriminative ability has limited their translation beyond clinical trial recruitment.\(^8\) The FDA recently approved the first AKI point-of-care biomarker device called NephroCheck.\(^8\) Its positive predictive value to diagnose KDIGO stage 2 or 3 AKI is 49% and the negative predictive value is 97%, suggesting its strength might lie in the ability to identify patients at low risk for severe AKI.\(^8\) NephroCheck measures urinary levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) and IGFBP7, which are cell cycle arrest biomarkers. It is hypothesized that TIMP-2*IGFBP7 may also serve a protective effect on the kidney by minimizing the proliferation of damaged cells. As for CKD progression after AKI, there remains no FDA-qualified biomarker to measure continued injury or intrarenal fibrosis, which limits the detection of maladaptive repair and the potential efficacy of treatments that target these pathways. Other options for fibrosis measurement include magnetic resonance imaging (MRI) techniques, such as blood oxygen level-dependent MRI\(^8,5\) fibrosis-specific contrast agents,\(^8,6\) and elastography techniques\(^8,5\) whose clinical utility remains to be fully determined.

The above progress in primarily the recognition and diagnosis of AKI can help identify the challenges and opportunities that remain to translate basic knowledge of AKI into the prevention of CKD and ESRD at the bedside. First, most risk scores do not address the etiology of AKI or AKI subtypes/endophenotypes; the latter terms being the combination of clinical features, comorbidities, genetics, biomarker expression, and population-specific factors that contribute to its onset and progression.\(^1\) Even if high-risk patients for AKI and its sequelae can be identified early, therapeutic interventions are likely to be dependent on the cause or subtype of AKI. To address this obstacle, one suggested strategy is to focus on animal and human populations in whom the etiology of AKI is established, such as cardiac surgery, coronary angiography, and chemotherapy. This work will require kidney tissue from human samples with well-characterized causes and courses of AKI, which is currently underway by the National Institutes of Health (NIH).\(^10,8\) In addition to the right patient population, potential therapeutic interventions need to be administered at the right time. Delays may explain the lack of treatment benefit for electronic creatinine alert systems, but they also affect translational studies, such as in a multicenter study of recombinant IGF-1 that was administered as late as 6 days after the onset of AKI.\(^8\) This barrier reinforces the importance of concentrating research to causes of AKI with precise onsets, which is challenging for CKD progression after AKI where the exact timing of maladaptive repair remains poorly defined. It is possible that this gap may be filled by biomarkers to identify the transition to repair and fibrosis after AKI. However, AKI biomarkers have yet to realize their full potential. Their biologic actions are often not linked to therapeutic interventions, and their efficacy has traditionally been measured against serum creatinine rather than tissue samples or hard clinical outcomes. This practice has led the Acute Dialysis Quality Initiative to propose a framework that characterizes AKI using both functional and damage markers,\(^8\) and the same principles could extend to CKD progression after AKI using the combination of creatinine, biomarkers, and MRI. It also remains unclear how biomarker expression patterns differ across subtypes of AKI. Through the Kidney Precision Medicine Project, the NIH is accumulating kidney biopsy samples in patients with AKI which may inform subtype-specific and common mechanisms to target.\(^8\) It is unclear though how many of these samples will be from patients who develop CKD and ESRD after AKI. In the past, large interventional AKI trials have not followed patients long term,\(^8\) and most nephrologists do not routinely follow patients after even dialysis-requiring AKI.\(^9\) These latter points reinforce why much more is currently known about the prevention and treatment of hospitalized AKI, whereby the downstream consequences of CKD and ESRD may also be reduced.
A Path Forward?

Some of the aforementioned basic science and clinical barriers have been overcome, which may inform translational research strategies to improve outcomes for patients with AKI. Even in the absence of a targeted treatment, Meersch et al.92 reduced the absolute risk of AKI by 17% in patients undergoing cardiac surgery. This was accomplished by identifying high-risk patients with a validated cell cycle arrest biomarker (i.e., TIMP-2*IGFBP7) among a cohort with a single AKI etiology of known timing (i.e., cardiac surgery). The treatment in this randomized trial of 276 patients was a KDIGO bundle, comprising optimization of blood volume status and hemodynamics, avoidance of nephrotoxic drugs, and prevention of hyperglycemia. This study demonstrates how enrolling the right patient at the right time enhances the likelihood of finding an effect, as the number needed to treat would have been much higher than six had all 276 patients received the KDIGO bundle.93 Not only does this study provide an example of AKI prevention that may be translated to other well-defined etiologies such as coronary angiography and chemotherapy, but it also demonstrates a successful strategy that could be replicated when testing potential treatments for established AKI and progression to CKD after AKI.

Continuing this progress will require stakeholder engagement from clinicians, basic scientists, trialists, industry, and the FDA, which is already underway.10 One group conspicuously missing from these meetings is patients and their caregivers. Their involvement in AKI research could serve several functions, particularly idea prioritization, study design, and patient recruitment.94,95 Their role becomes even more important as expert groups recommend reverse translational approaches for AKI research to complement the traditional bench to bedside approach to treatment development.10

In short, reverse translation involves working backward by first defining patient populations, clinical trial designs, and end points, as well as maximizing knowledge of human AKI with mechanistic studies requiring human tissue. Then, animal models are identified to replicate the above patient population and develop therapies. Reverse translation may require more commitment and risk from patients and their caregivers, and so before this work is undertaken it is critical to understand their perspectives on research strategies for AKI and CKD in addition to their willingness to support both traditional and reverse translational research.

Conclusion

The opportunity to make advances in the prevention and treatment of AKI and its sequelae has never been greater. There have been major advances in understanding the biology of AKI, CKD, and the clinical infrastructure to predict...
and diagnose AKI rapidly. Multiple workgroups have assembled,\textsuperscript{10-13} with different yet complementary translational strategies proposed to overcome the well-described challenges (Figure 1). Whether the focus is on individual AKI subtypes or common mechanistic pathways that drive CKD after AKI, more knowledge of human AKI at the tissue level is needed along with validation of these discoveries in multiple animal models that mirror the complexities of human AKI. Promising therapeutic agents should then be tested in high-risk patients with known causes of AKI in whom the timing of AKI onset or transition to maladaptive repair can also be determined. Biomarkers may help guide the timing of treatment delivery and should be incorporated in both the study of human and animal AKI. Teamwork and stakeholder engagement will be critical to these efforts, which must involve patients given the increasing emphasis on human tissue to guide AKI research. These new patient-centered research approaches and flexible translational strategies provide optimism that therapeutic interventions for the prevention and treatment of AKI will soon be available.

**Ethics Approval and Consent to Participate**
This is a review article and does not involve any intervention on patients.

**Consent for Publication**
All authors consent to the publication of this research.

**Availability of Data and Materials**
This study is a review of previously published data and materials.

**Declaration of Conflicting Interests**
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: S.A.S. and C.G. are supported by the Kidney Research Scientist Core Education and National Training (KRESCENT) Program New Investigator Award (co-funded by the Kidney Foundation of Canada, Canadian Society of Nephrology, and Canadian Institutes of Health Research).

**ORCID iD**
Casimiro Gerarduzzi https://orcid.org/0000-0001-7098-1455

**References**
1. Zeng X, McMahon GM, Brunelli SM, Bates DW, Waikar SS. Incidence, outcomes, and comparisons across definitions of AKI in hospitalized individuals. *Clin J Am Soc Nephrol*. 2014;9(1):12-20. doi:10.2215/CJN.02730313.

2. Susantitaphong P, Cruz DN, Cerda J, et al. World incidence of AKI: a meta-analysis. *Clin J Am Soc Nephrol*. 2013;8(9):1482-1493. doi:10.2215/CJN.00710113.

3. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. *J Am Soc Nephrol*. 2005;16(11):3365-3370. doi:10.1681/ASN.2004090740.

4. Wald R, Quinn RR, Adhikari NK, et al. Risk of chronic dialysis and death following acute kidney injury. *Am J Med*. 2012;125(6):585-593. doi:10.1016/j.amjmed.2012.01.016.

5. Wald R, Quinn RR, Luo J, et al. Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. *JAMA*. 2009;302(11):1179-1185. doi:10.1001/jama.2009.1322.

6. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. *Kidney Int*. 2012;81(5):442-448. doi:10.1038/ki.2011.379.

7. Goldstein SL, Jaber BL, Faubel S, Chawla LS. AKI transition of care: a potential opportunity to detect and prevent CKD. *Clin J Am Soc Nephrol*. 2013;8(3):476-483. doi:10.2215/CJN.12011112.

8. Bouchard J, Acharya A, Cerda J, et al. A prospective international multicenter study of AKI in the intensive care unit. *Clin J Am Soc Nephrol*. 2015;10(8):1324-1331. doi:10.2215/CJN.04360514.

9. Waikar SS, Liu KD, Chertow GM. Diagnosis, epidemiology and outcomes of acute kidney injury. *Clin J Am Soc Nephrol*. 2008;3(3):844-861. doi:10.2215/CJN.05191107.

10. Zuk A, Palevsky PM, Fried L, et al. Overcoming translational barriers in acute kidney injury: a report from an NIDDK workshop. *Clin J Am Soc Nephrol*. 2018;13(7):1113-1123. doi:10.2215/CJN.06820617.

11. Basile DP, Bonventre JV, Mehta R, et al. Progression after AKI: understanding maladaptive repair processes to predict and identify therapeutic treatments. *J Am Soc Nephrol*. 2016;27(3):687-697. doi:10.1681/ASN.2015030309.

12. Okusa MD, Rosner MH, Kellum JA, Ronco C. Therapeutic targets of human AKI: harmonizing human and animal AKI. *J Am Soc Nephrol*. 2016;27(1):44-48. doi:10.1681/ASN.2015030233.

13. deCaestecker M, Humphreys BD, Liu KD, et al. Bridging translation by improving preclinical study design in AKI. *J Am Soc Nephrol*. 2015;26(12):2905-2916. doi:10.1681/ASN.2015070832.

14. Fu Y, Tang C, Cai J, Chen G, Zhang D, Dong Z. Rodent models of AKI-CKD transition. *Am J Physiol Renal Physiol*. 2018;315(4):F1098-F1106. doi:10.1152/ajprenal.00199.2018.

15. Venkatachalam MA, Griffin KA, Lan R, Geng H, Saikumar P, Bidani AK. Acute kidney injury: a springboard for progress in chronic kidney disease. *Am J Physiol Renal Physiol*. 2010;298(5):F1078-E1094. doi:10.1152/ajprenal.00017.2010.

16. Basile DP. The endothelial cell in ischemic acute kidney injury: implications for acute and chronic function. *Kidney Int*. 2007;72(2):151-156. doi:10.1038/sj.ki.5002312.

17. Xiao L, Zhou D, Tan RJ, et al. Sustained activation of Wnt/beta-catenin signaling drives AKI to CKD progression. *J Am Soc Nephrol*. 2016;27(6):1727-1740. doi:10.1681/ASN.2015040449.

18. Wei Q, Dong Z. Mouse model of ischemic acute kidney injury: technical notes and tricks. *Am J Physiol Renal Physiol*. 2012;303(11):F1487-F1494. doi:10.1152/ajprenal.00352.2012.

19. Basile DP, Donohoe D, Roethe K, Osborn JL. Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. *Am J Physiol Renal Physiol*. 2001;281(5):F887-F899. doi:10.1152/ajprenal.2001.281.5.F887.
20. Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med. 2010;16(5):535-543. 531p following 143. doi:10.1038/nm.2144.

21. Delbridge MS, Shrestha BM, Raftery AT, El Nahas AM, Haylor JL. The effect of body temperature in a rat model of renal ischemia-reperfusion injury. Transplant Proc. 2007;39(10):2983-2985. doi:10.1016/j.transproceed.2007.04.028.

22. Zager RA, Gmur DJ, Bredl CR, Eng MJ. Degree and time sequence of hypothermic protection against experimental ischemic acute renal failure. Circ Res. 1989;65(5):1263-1269. doi:10.1161/01.res.65.5.1263.

23. Cracun FL, Ajay AK, Hoffmann D, et al. Pharmacological and genetic depletion of fibrinogen protects from kidney fibrosis. Am J Physiol Renal Physiol. 2014;307(4):F471-F484. doi:10.1152/ajprenal.00189.2014.

24. Szczypka MS, Westover AJ, Clouthier SG, Ferrara JL, Humes HD. Rare incorporation of bone marrow-derived cells into kidney after folic acid-induced injury. Stem Cells. 2005;23(1):44-54. 10.1634/stemcells.2004-0111.

25. Sanz AB, Justo P, Sanchez-Nino MD, et al. The cytokine TWEAK modulates renal tubulointerstitial inflammation. J Am Soc Nephrol. 2008;19(4):695-703. 10.1681/ASN.2007050577.

26. Gupta A, Puri V, Sharma R, Puri S. Folic acid induces acute renal failure (ARF) by enhancing renal prooxidant state. Exp Toxicol Pathol. 2012;64(3):225-232. 10.1016/j.etp.2010.08.010.

27. Ozkok A, Edelstein CL. Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int. 2014;2014:967826. doi:10.1155/2014/967826.

28. Heyman SN, Lieberthal W, Rogiers P, Bonventre JV. Animal models of acute tubular necrosis. Curr Opin Crit Care. 2002;8:526-534.

29. Katagiri D, Hamasaki Y, Doi K, et al. Interstitial renal fibrosis due to multiple cisplatin treatments is ameliorated by semicarbazide-sensitive amine oxidase inhibition. Kidney Int. 2016;89(2):374-385. 10.1038/ki.2015.327.

30. Sharp CN, Doll MA, Dupre TV, et al. Repeated administration of low-dose cisplatin in mice induces fibrosis. Am J Physiol Renal Physiol. 2016;310(6):F560-F568. doi:10.1152/ajprenal.00512.2015.

31. Torres R, Velazquez H, Chang JJ, et al. Three-dimensional morphology of multiphoton microscopy with clearing in a model of cisplatin-induced CKD. J Am Soc Nephrol. 2016;27(4):1102-1112. 10.1681/ASN.2015010079.

32. Sharp CN, Doll MA, Megyesi J, Oropilla GB, Beverly LJ, Siskind LJ. Subclinical kidney injury induced by repeated cisplatin administration results in progressive chronic kidney disease. Am J Physiol Renal Physiol. 2018;315(1):F161-F172. doi:10.1152/ajprenal.00512.2016.

33. Chang SY, Weber EJ, Sidorenko VS, et al. Human liver-kidney model elucidates the mechanisms of aristolochic acid nephrotoxicity. JCI Insight. 2017;2(22):e95978. 10.1172/jci.insight.95978.

34. Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 2008;74(2):158-169. doi:10.1038/ki.2008.129.

35. Depierreux M, VanDamme B, VandenHoute K, Vanherweghem JL. Pathologic aspects of a newly described nephropathy related to the prolonged use of Chinese herbs. Am J Kidney Dis. 1994;24(2):172-180.

36. Romanov V, Whyard TC, Walter WC, Grollman AP, Rosenquist T. Aristolochic acid-induced apoptosis and G2 cell cycle arrest depends on ROS generation and MAP kinases activation. Arch Toxicol. 2015;89(1):47-56. 10.1007/s00204-014-1249-z.

37. Bonventre JV, Yang L. Cellular pathophysiology of ischamic acute kidney injury. J Clin Invest. 2011;121(11):4210-4221. doi:10.1172/JCI45161.

38. Ying Y, Kim J, Westphal SN, Long KE, Padenlam BJ. Targeted deletion of p53 in the proximal tubule prevents ischemic renal injury. J Am Soc Nephrol. 2014;25(12):2707-2716. 10.1681/ASN.2013121270.

39. Zhang D, Li Y, Wei Q, et al. Tubular p53 regulates multiple genes to mediate AKI. J Am Soc Nephrol. 2014;25(10):2278-2289. 10.1681/ASN.2013089092.

40. Volanti FA, Falke LL, Nguyen TQ, Goldschmeding R. Cellular senescence in the aging and diseased kidney. J Cell Commun Signal. 2018;12(1):69-82. 10.1007/s12079-017-0434-2.

41. Ma FY, Sachchithanantham M, Flanc RS, Nikolic-Paterson DJ. Mitogen activated protein kinases in renal fibrosis. Front Biosci (Schol Ed). 2009;1:171-187.

42. Basile DP. The transforming growth factor beta system in kidney disease and repair: recent progress and future directions. Curr Opin Nephrol Hypertens. 1999;8(1):21-30.

43. Watanabe J, Takiyama Y, Honjo J, et al. Role of IGFBP7 in diabetic nephropathy: TGF-β1 induces IGFBP7 via Smad2/4 in human renal proximal tubular epithelial cells. PLoS ONE. 2016;11(3):e0150897. 10.1371/journal.pone.0150897.

44. Nacchemia-Arbel Y, Barkan D, Pizov G, et al. IL-6/IL-6R axis plays a critical role in acute kidney injury. J Am Soc Nephrol. 2008;19(6):1106-1115. 10.1681/ASN.2007070744.

45. Ranganathan P, Jayakumar C, Ramesh G. Proximal tubule-specific overexpression of netrin-1 suppresses acute kidney injury-induced interstitial fibrosis and glomerulosclerosis through suppression of IL-6/STAT3 signaling. Am J Physiol Renal Physiol. 2013;304(8):F1054-F1065. doi:10.1152/ajprenal.00650.2012.

46. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest. 2002;110(6):835-842. 10.1172/JCI45160.

47. Carlsson AC, Nordquist L, Larsson TE, et al. Soluble tumor necrosis factor receptor 1 is associated with glomerular filtration rate progression and incidence of chronic kidney disease in two community-based cohorts of elderly individuals. Cardiorenal Med. 2015;5(4):278-288. 10.1159/000435863.

48. Oh DJ, Kim HR, Lee MK, Woo YS. Profile of human beta-defensins 1, 2 and proinflammatory cytokines (TNF-alpha, IL-6) in patients with chronic kidney disease. J Am Soc Nephrol. 2016;11(3):e0150897. doi:10.1371/journal.pone.0150897.

49. Yang B, Lan S, Dieude M, et al. Caspase-3 is a pivotal regulator of microvascular rarefaction and renal fibrosis after ischemia-reperfusion injury. J Am Soc Nephrol. 2018;29(7):1900-1916. 10.1681/ASN.2017050581.

50. Linkermann A. Nonapoptotic cell death in acute kidney injury and transplantation. Kidney Int. 2016;89(1):46-57. doi:10.1016/j.kint.2015.10.008.
51. Linkermann A, Hackl MJ, Kunzendorf U, Walczak H, Krautwald S, Jevnikar AM. Necroptosis in immunity and ischemia-reperfusion injury. Am J Transplant. 2013;13(11):2797-2804. doi:10.1111/a jt.12448.

52. Arai S, Kitada K, Yamazaki T, et al. Apoptosis inhibitor of macrophage protein enhances intraluminal debris clearance and ameliorates acute kidney injury in mice. Nat Med. 2016;22(2):183-193. doi:10.1038/nm.4012.

53. Reddy MA, Natarajan R. Recent developments in epigenetics of acute and chronic kidney diseases. Kidney Int. 2015;88(2):250-261. doi:10.1038/ki.2015.148.

54. Smyth LJ, McKay GJ, Maxwell AP, McKnight AJ. DNA hypermethylation and DNA hypomethylation is present at different loci in chronic kidney disease. Epigenetics. 2014;9(3):366-376. doi:10.4161/epi.27161.

55. Susztak K. Understanding the epigenetic syntax for the genetic alphabet in the kidney. J Am Soc Nephrol. 2014;25(1):10-17. doi:10.1681/ASN.2013050461.

56. Zager RA, Johnson AC. Renal ischemia-reperfusion injury upregulates histone-modifying enzyme systems and alters histone expression at proinflammatory/proliferative genes. Am J Physiol Renal Physiol. 2009;296(5):F1032-F1041. doi:10.1152/ajprenal.00410.2009.

57. Bechtel W, McGoohan S, Zeisberg EM, et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med. 2010;16:544-550. doi:10.1038/nm.2135.

58. Liu J, Livingstone MJ, Dong G, et al. Histone deacetylase inhibitors protect against cisplatin-induced acute kidney injury by activating autophagy in proximal tubular cells. Cell Death Dis. 2018;9(3):322. doi:10.1038/s41419-018-0374-7.

59. Ranganathan P, Hamad R, Mohamed R, Jayakumar C, Muthusamy T, Ramesh G. Histone deacetylation-mediated silencing of AMWAP expression contributes to cisplatin nephrotoxicity. Kidney Int. 2016;89(2):317-326. doi:10.1038/ki.2015.326.

60. Novitskaya T, McDermott L, Zhang KX, et al. A PTBA small molecule enhances recovery and reduces postinjury fibrosis after aristolochic acid-induced kidney injury. Am J Physiol Renal Physiol. 2014;306(5):F496-F504. doi:10.1152/ajprenal.00412.2009.

61. Dong G, Luo J, Kumar V, Dong Z. Inhibitors of histone deacetylases suppress cisplatin-induced apoptosis in renal tubular cells. Am J Physiol Renal Physiol. 2010;298(2):F293-F300. doi:10.1152/ajprenal.00534.2013.

62. He L, Wei Q, Liu J, et al. AKI on CKD: heightened injury, apoptosis and fibrosis in renal tubular cells. Am J Physiol Renal Physiol. 2010;298(2):F293-F300. doi:10.1152/ajprenal.00534.2009.

63. Djudjaj S, Chatziantoniou C, Raffetseder U, et al. Notch-3 receptor activation drives inflammation and fibrosis following tubulointerstitial kidney injury. J Pathol. 2012;228(3):286-299. doi:10.1002/path.4076.

64. Murea M, Park JK, Sharma S, et al. Expression of Notch pathway proteins correlates with albuminuria, glomerulosclerosis, and renal function. Kidney Int. 2010;78(5):514-522. doi:10.1038/ki.2010.172.

65. DiRocco DP, Kobayashi A, Takeo MM, McMahon AP, Humphreys BD. Wnt4/beta-catenin signaling in medullary kidney myofibroblasts. J Am Soc Nephrol. 2013;24(9):1399-1412. doi:10.1681/ASN.2012050512.
81. Parikh CR, Coca SG, Thiessen-Philbrook H, et al. Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. *J Am Soc Nephrol*. 2011;22(9):1748-1757. doi:10.1681/ASN.2010121302.

82. Parikh CR, Devarajan P, Zappitelli M, et al. Postoperative biomarkers predict acute kidney injury and poor outcomes after pediatric cardiac surgery. *J Am Soc Nephrol*. 2011;22(9):1737-1747. doi:10.1681/ASN.2010111163.

83. Bihorac A, Chawla LS, Shaw AD, et al. Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication. *Am J Respir Crit Care Med*. 2014;189(8):932-939. doi:10.1164/rccm.201401-0077OC.

84. Hoste EA, McCullough PA, Kashani K, et al. Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers. *Nephrol Dial Transplant*. 2014;29(11):2054-2061. doi:10.1093/ndt/gfu292.

85. Inoue T, Kozawa E, Okada H, et al. Noninvasive evaluation of kidney hypoxia and fibrosis using magnetic resonance imaging. *J Am Soc Nephrol*. 2011;22(8):1429-1434. doi:10.1681/ASN.2010111143.

86. Korsmo MJ, Ebrahimi B, Eirin A, et al. Magnetic resonance elastography noninvasively detects in vivo renal medullary fibrosis secondary to swine renal artery stenosis. *Invest Radiol*. 2013;48(2):61-68. doi:10.1097/RLI.0b013e31827a4990.

87. Norton JM, Ketchum CJ, Narva AS, Star RA, Rodgers GP. Complementary initiatives from the NIDDK to advance kidney health. *Clin J Am Soc Nephrol*. 2017;12(9):1544-1547. doi:10.2215/CJN.02120217.

88. Hirschberg R, Koppel J, Lipsett P, et al. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. *Kidney Int*. 1999;55(6):2423-2432. doi:10.1046/j.1523-1755.1999.00463.x.

89. Murray PT, Mehta RL, Shaw A, et al. Potential use of biomarkers in acute kidney injury: report and summary of recommendations from the 10th Acute Dialysis Quality Initiative consensus conference. *Kidney Int*. 2014;85(3):513-521. doi:10.1038/ki.2013.374.

90. Palevsky PM, Zhang JH, O'Connor TZ, et al. Intensity of renal support in critically ill patients with acute kidney injury. *N Engl J Med*. 2008;359(1):7-20. doi:10.1056/NEJMoa0802639.

91. Harel Z, Wald R, Bargman JM, et al. Nephrologist follow-up improves all-cause mortality of severe acute kidney injury survivors. *Kidney Int*. 2013;83(5):901-908. doi:10.1038/ki.2012.451.

92. Meersch M, Schmidt C, Hoffmeier A, et al. Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. *Intensive Care Med*. 2017;43(11):1749. doi:10.1007/s00134-017-4735-y.

93. Kellum JA. Acute kidney injury: AKI: the myth of inevitability is finally shattered. *Nat Rev Nephrol*. 2017;13(3):140-141. doi:10.1038/nrneph.2017.11.

94. Molnar AO, Barua M, Konvalinka A, Schick‐Makaroff K. Patient engagement in kidney research: opportunities and challenges ahead. *Can J Kidney Health Dis*. 2017;4:2054358117740583. doi:10.1177/2054358117740583.

95. Demian MN, Lam NN, Mac-Way F, et al. Opportunities for engaging patients in kidney research. *Can J Kidney Health Dis*. 2017;4:2054358117703070. doi:10.1177/2054358117703070.